Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

Cancer

Volumn 109, Issue 9, 2007, Pages 1804-1810

  Witzig, Thomas E ^a   Molina, Arturo ^b   Gordon, Leo I ^c   Emmanouilides, Christos ^d   Schilder, Russell J ^e   Flinn, Ian W ^f   Darif, Mohamed ^b   Macklis, Roger ^g   Vo, Katie ^b   Wiseman, Gregory A ^a  

^a MAYO CLINIC   (United States)

^b BIOGEN   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Fox Chase Comprehensive Cancer Center   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

90Y ibritumomab tiuxetan; Non Hodgkin lymphoma (NHL); Radioimmunotherapy; Time to progression (TTP)

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; IBRITUMOMAB TIUXETAN IN 111; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, B-CELL; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 34247561116     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22617     Document Type: Article

References (23)

1. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossmin SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424-1433.
2. Zelenetz AD. Radioimmunotherapy for lymphoma. Curr Opin Oncol. 1999;11:375-380.
3. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
4. Vriesendorp HM, Herpst JM, Germack MA, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol. 1991;9:918-928 [erratum, J Clin Oncol. 1991;9:1516].
5. Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
6. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
7. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429-4431.
8. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
9. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
10. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99:4336-4342.
11. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:1263-1270.
12. Schilder R, Molina A, Bartlett N, et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radio pharm. 2004;19:478-481.
13. Gordon LI, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004;5: 98-101.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573.
16. Kaminski MS, Tuck M, Estes J, et al. 1311-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
17. 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial [abstract]. Proc Am Soc Clin Oncol. 2004;23:560.
18. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:629-636.
19. 90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma [abstract]. Blood. 2004;104:720a.
20. Justice T, Martenson JA Jr, Wiseman G, Witzig T. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer. 2006;107:433-438.
21. Ansell SM, Schilder RJ, Pieslor PC, et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma. 2004;5:202-204.
22. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002;20: 3885-3890.
23. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomah. J Clin Oncol. 2005;23:7985-7993.